71PPhase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. (17th December 2018) - Owonikoko, T K; Papadopoulos, K P; Johnson, M L; Gil Martín, M; Moreno, V; Salama, A K; Calvo, E; Yee, N S; Safran, H; Aljumaily, R; Mahadevan, D; Niu, J; et al.